凋亡抑制在急性白血病和骨髓增生异常综合征中的作用
The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome.
作者信息
McBride Amanda, Houtmann Sarah, Wilde Lindsay, Vigil Carlos, Eischen Christine M, Kasner Margaret, Palmisiano Neil
机构信息
Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.
Department of Medicine, Thomas Jefferson University, Philadelphia, PA, United States.
出版信息
Front Oncol. 2019 Mar 27;9:192. doi: 10.3389/fonc.2019.00192. eCollection 2019.
Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.
避免细胞凋亡是包括急性白血病和骨髓增生异常综合征在内的恶性肿瘤用于增殖和抵抗化疗的关键机制。最近，抗凋亡蛋白BCL-2抑制剂维奈克拉已被批准用于治疗不适合化疗的老年初治急性髓系白血病患者。本文综述了目前正在研发的用于治疗急性髓系白血病、急性淋巴细胞白血病和骨髓增生异常综合征的细胞凋亡抑制剂的临床前和临床数据。
Zotero 插件